These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33364840)

  • 21. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    Kindler HL; Hammel P; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; Bordia S; McGuinness D; Cui K; Locker GY; Golan T
    J Clin Oncol; 2022 Dec; 40(34):3929-3939. PubMed ID: 35834777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden.
    Polyzoi M; Ekman M; Reithmeier A; Jacob J; Karlsson E; Bertranou E; Linderholm B; Hettle R
    Pharmacoecon Open; 2024 Mar; 8(2):277-289. PubMed ID: 38093030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia.
    Yong CM; Yehgambaram PAP; Lee SWH
    PLoS One; 2024; 19(2):e0298130. PubMed ID: 38300930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
    Moya-Alarcón C; González-Domínguez A; Ivanova-Markova Y; Gimeno-Ballester V; Barretina-Ginesta MP; Pérez-Fidalgo JA; Redondo A
    Gynecol Oncol; 2022 Feb; 164(2):406-414. PubMed ID: 34844775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma based on the NEOCRTEC5010 trial.
    Zhan M; Zheng H; Yang Y; Xu T; Li Q
    Radiother Oncol; 2019 Dec; 141():27-32. PubMed ID: 31431378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04.
    Zhan M; Huang Z; Xu T; Xu X; Zheng H; Wu F
    Front Public Health; 2023; 11():1049947. PubMed ID: 37457280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
    Kindler HL; Yoo HK; Hettle R; Cui KY; Joo S; Locker GY; Golan T
    Cancer; 2023 May; 129(9):1411-1418. PubMed ID: 36811344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study.
    M'Baloula J; Tougeron D; Boilève A; Jeanbert E; Guimbaud R; Ben Abdelghani M; Durand A; Turpin A; Quesada S; Blanc JF; Artru P; Toullec C; Trouilloud I; Pellat A; Touchefeu Y; Pinot J; Caroli-Bosc FX; Taïeb J; Doat S; Bouché O; Védie AL; de Mestier L; Muller M
    Eur J Cancer; 2024 Nov; 212():115051. PubMed ID: 39366210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of olaparib, a PARP inhibitor, for patients with metastatic castration-resistant prostate cancer in China and United States.
    Xu C; Cai J; Zhuang J; Zheng B; Chen L; Sun H; Zheng G; Wei X; Liu M
    Ann Transl Med; 2022 Aug; 10(15):830. PubMed ID: 36034977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of
    Saito S; Nakazawa K; Nagahashi M; Ishikawa T; Akazawa K
    Per Med; 2019 Nov; 16(6):439-448. PubMed ID: 31692405
    [No Abstract]   [Full Text] [Related]  

  • 33. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
    Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic Evaluation of Population-Based
    Manchanda R; Sun L; Patel S; Evans O; Wilschut J; De Freitas Lopes AC; Gaba F; Brentnall A; Duffy S; Cui B; Coelho De Soarez P; Husain Z; Hopper J; Sadique Z; Mukhopadhyay A; Yang L; Berkhof J; Legood R
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
    Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China.
    Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
    BMJ Open; 2020 Nov; 10(11):e040691. PubMed ID: 33243806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
    Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U
    Lancet Oncol; 2014 Jul; 15(8):852-61. PubMed ID: 24882434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
    Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
    JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modeling health outcomes associated with BRCA testing and treatment strategies for patients with metastatic pancreatic cancer.
    Agnihotri N; Ambavane A; Fan L; Li W; Yoo H; Joo S; Muston D
    Pancreatology; 2024 Mar; 24(2):271-278. PubMed ID: 38286712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.